CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge-based biopharmaceutical company today, has entered into an agreement with Innovata plc (LSE: IOV) to acquire certain patent rights covering a proprietary synthetic method for the manufacture of its lead product M6G. Terms of the deal were not disclosed.
